Loading
A phase 2 trial of EIK1001, Pembrolizumab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Eikon Therapeutics, active and no longer recruiting.
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC is a phase 2 interventional study registered as NCT06246110 by Eikon Therapeutics, with 70 participants enrolled, started 2024-02-06 and due to reach its primary completion in 2026-12. Interventions recorded: EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed and Carboplatin.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Carboplatin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.